Microdevice for Psoriasis and Atopic Dermatitis
This study is testing a small device, about the size of a grain of rice, for people with atopic dermatitis (eczema) or psoriasis. This microdevice holds tiny amounts of FDA-approved medications like Triamcinolone, 5-Fluorouracil, Calcipotriene, and Tapinarof. These medications will be released directly into your skin at very low levels. The goal is to see if the device is safe and can help predict how your skin will react to standard treatments. We'll also look at how these reactions relate to your genetic information and overall treatment results. The study aims to enroll 10 participants and is currently unclear on its recruitment status.
- Study design
- This interventional study plans to enroll 10 participants to test a microdevice directly on the skin.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events and device assessment for up to 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Raymond Cho, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with adverse events1 year
The safety of microdevice placement and removal will be based on assessment of adverse events.
- Proportion of retrieved devices with assessable tissue1 year
The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.